Share page on LinkedIn

Innovation in clinical trial methodologies

Lessons learned during the corona pandemic

The Coronavirus pandemic is an accelerator for digitalisation in many industries

In a timely new book edited by Dr Peter Schueler, Senior VP Drug Development Services, Neurosciences, at ICON plc, authors explore how, by learning the right lessons, the industry and wider society could be entering a golden age of drug development.

The Coronavirus pandemic is an accelerator for digitalisation in many industries, including clinical trials. Presenting a selection of completely updated chapters from Re-Engineering Clinical Trials that feature innovative options and methods in clinical trials, the book is a concise, necessary investigation on best practices, alternative study concepts requiring fewer patients, studies with less patient interaction, the design of "virtualised" protocols, and moving from data to decisions.

Pharmacologists, physicians and clinical researchers involved in the process of clinical development and clinical trial design will all find this an essential resource.


ICON is pleased to offer a code for a 30% discount on individual purchases, and a 50% discount on bulk purchases (more than 10) – simply complete the short form to receive your discount code and link to purchase the book.

Innovation in clinical trial methodologies

Dr Peter Schueler chats to Applied Clinical Trials on how CROs have changed over the years, his role in editing the 'Innovation in Clinical Trial Methodologies' book, and risk aversion versus innovation in the life sciences industry.

Listen to the podcast

Table of contents

Section 1 Introduction

1. Is the Covid pandemic an accelerator for digitalisation?

2. Best practices for streamlined development

Section 2 Alternative study concepts requiring less patients

3. Use of historic data

4. Adaptive and platform trials

5. A vision: Studies without patients

Section 3 Studies with less patient interaction

6. Home Nursing replacing site visits

7. Telemedicine replacing site visits

Section 4 Design of "virtualized" protocols

8. Data mining for better protocols

9. Patient-centric registries for population enrichment

10. Make a protocol "patient centric"

11. The use of new digital endpoints

12. Regulations for apps in clinical trials

13. The role of the site and the patient

14. A real virtual trial

Section 5 From data to decisions

15. Data standards against data overload

16. Data analytics for operational excellence

17. Taking control of high data volume

18. Share the (digital) knowledge based on quality data

Section 6 Conclusions